Lexicon Pharmaceuticals, Inc. (LXRX) Stock Price & Analysis

Lexicon Pharmaceuticals, Inc. (LXRX) closed at USD 1.49 on Wednesday, October 28, 2026, up 0.34% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 1.48; the Oct 28, 2026 session ranged USD 1.43–1.49 on volume of 1,618,040 shares. Market capitalization is $660.76M, with a 52-week range of USD 1.1–2.68 (NCM). Source: Nexqual, retrieved October 29, 2026 at 13:27 UTC.

Also available as compact Markdown for AI agents: nexqual.com/LXRX.md

Key facts (LXRX)

• Last four reported quarters (through Jun 30, 2026): revenue $41.5M, net income -$61.1M (-147.4% margin) (SEC filings).
• Analysts: Buy (mean 2.17 on a 1–5 scale) (6 analysts), mean target USD 4.47 (range 1.69–8).
• Total return with dividends: 1Y +12.0% vs S&P 500 +13.6%; 5Y -71.9% vs S&P 500 +79.8%.
• Next earnings: 2026-11-05, EPS estimate USD -0.05, revenue estimate $4.1M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (LXRX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (LXRX)

P/S 15.9x · EV/Sales 12.6x · P/B 3.8x · Earnings yield -9.25% · Net cash $139M · EV $522M

Analysts (LXRX)

Consensus Buy (mean 2.17 on a 1–5 scale), 6 analysts; mean target USD 4.47 (low 1.69, high 8).

Rating changes, last 120 days:

Total return (dividends reinvested) (LXRX)

LXRX earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

LXRX recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

LXRX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 5, 2026.

LXRX company outlook (results filed Aug 6, 2026)

• “The final study population included a substantial majority of patients with nHCM, providing a robust opportunity to evaluate sotagliflozin in a patient group for whom effective treatment options remain limited, as well as a meaningful cohort of patients with oHCM. • Lexicon continues to expect topline results in the first quarter of 2027.”
• “Food and Drug Administration (FDA) as being adequate to support a resubmission of the company's New Drug Application (NDA), which Lexicon anticipates will occur in the fourth quarter of 2026 based on current estimated timing of data collection. • The safety data received to date from this open-label trial continue to support the resubmission.”
• “Viatris anticipates regulatory decisions in Australia and Canada and regulatory submissions in other markets in 2026.”
• “The Phase 1 program is expected to be completed in the first quarter of 2027. • Under the terms of Lexicon's exclusive license agreement with Novo Nordisk, Lexicon received an upfront payment of $45 million and two $10 million payments related to clinical development.”

Quoted word-for-word from the SEC 8-K results press release.

LXRX analyst estimates and revisions

LXRX options: expected move

Options price a move of about ±23.2% (±$0.35) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±13.1% on average.

30-day implied volatility 94.4% vs 58.5% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 13:27 UTC)

Technical Analysis (LXRX)

Nexqual's technical model rates LXRX "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 13:27 UTC.

Analyst Ratings (LXRX)

Wall Street analysts rate LXRX "Buy" based on 6 analysts, with a mean price target of USD 4.47 (range USD 1.69–8), per Nexqual as of October 29, 2026 at 13:27 UTC.

Earnings (LXRX)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 13:27 UTC.

Financials & Fundamentals (LXRX)

Source: Nexqual, October 29, 2026 at 13:27 UTC.

Financial Health Score (LXRX)

Nexqual rates Lexicon Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 13:27 UTC.

Ownership (LXRX)

Source: Nexqual, October 29, 2026 at 13:27 UTC.

Leadership (LXRX)

Lexicon Pharmaceuticals, Inc. is led by Michael S. Exton, CEO & Director, per Nexqual as of October 29, 2026 at 13:27 UTC.

Major Backers & Investors (LXRX)

Notable institutional backers of Lexicon Pharmaceuticals, Inc. include Artal Group S.A., FMR, LLC, Siren, L.L.C., according to Nexqual as of October 29, 2026 at 13:27 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 13:27 UTC.

From Lexicon Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)

Key Strengths & Strategy (as disclosed to the SEC)

• Food and Drug Administration, or FDA, issued complete response letters regarding our New Drug Application, or NDA, for ZYNQUISTA in type 1 diabetes in March 2019 and December 2024.
• We use "sotagliflozin" when referring to our development for HCM, "ZYNQUISTA" when referring to our development for type 1 diabetes and "INPEFA" when referring to our FDA-approved drug.
• Not only must a company have appropriate substantiation to support claims made about a drug, under the FDA's current interpretation of relevant laws, a company can make only those claims relating to safety and efficacy that are for indications for which the FDA has approved the drug and are otherwise consistent with the FDA-approved label for the drug.
• The FDA has various programs, including Fast Track, priority review and accelerated approval, which are intended to expedite or simplify the process for developing and reviewing promising drugs, or to provide for the approval of a drug on the basis of a surrogate endpoint.

Partnerships

• We entered into an exclusive license agreement with Novo Nordisk A/S in March 2025 under which we granted Novo Nordisk an exclusive, worldwide, royalty-bearing right and license to develop, manufacture and commercialize LX9851.
• We entered into an exclusive license agreement with Viatris Inc. in October 2024 under which we granted Viatris an exclusive, royalty-bearing right and license to develop and commercialize sotagliflozin in the licensed territory.

Legal & Regulatory Risks (Item 1A, quoted)

• Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our and our collaborators' ability to commercialize products.
• We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.
• We and our collaborators are subject to extensive and rigorous ongoing regulation relating to any products that we or our collaborators may develop.
• Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may negatively affect our revenues and prospects for profitability.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 13:27 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt